Abstract
Considering age is the greatest risk factor for many neurodegenerative diseases, aging, in particular aging of the immune system, is the most underappreciated and understudied contributing factor in the neurodegeneration field. Genetic variation around the LRRK2 gene affects risk of both familial and sporadic Parkinson’s disease (PD). The leucine-rich repeat kinase 2 (LRRK2) protein has been implicated in peripheral immune signaling, however, the effects of an aging immune system on LRRK2 function have been neglected to be considered. We demonstrate here that the R1441C mutation induces a hyper-responsive phenotype in macrophages from young female mice, characterized by increased effector functions, including stimulation-dependent antigen presentation, cytokine release, phagocytosis, and lysosomal function. This is followed by age-acquired immune cell exhaustion in a Lrrk2-kinase-dependent manner. Immune-exhausted macrophages exhibit suppressed antigen presentation and hypophagocytosis, which is also demonstrated in myeloid cells from R1441C and Y1699C-PD patients. Our novel findings that LRRK2 mutations confer immunological advantage at a young age but may predispose the carrier to age-acquired immune cell exhaustion have significant implications for LRRK2 biology and therapeutic development. Indeed, LRRK2 has become an appealing target in PD, but our findings suggest that more research is required to understand the cell-type specific consequences and optimal timing of LRRK2-targeting therapeutics.
One Sentence Summary The R1441C-LRRK2 mutation causes an age-acquired immune cell exhaustion in macrophages in a sex-dependent manner
Competing Interest Statement
MGT is a current advisor/consultant for INmune Bio, Merck, Forward Therapeutics, Weston Foundation, Alzheimers Association, Bright Focus Foundation, New Horizons Research, SciNeuro, NysnoBio, Longevity, iMetabolic Pharma, Novo Nordisk, and iMMvention and an AE for Science Advances. N.B. received honaria from Abbott, Abbvie, Biogen, Biomarin, Bridgebio, Centogene, Esteve, Ipsen, Merz, Teva, Zambon. CK is medical advisor to Centogene, Retromer Therapeutics, and Takeda and Speakers Honoraria from Desitin and Bial. All other authors hold no competing interests.
Footnotes
Analysis was repeated comparing age across our different assays. males and females are still analyzed and presented separately. Manuscript has been revised in response to reviewers comments